- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02576496
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Study Overview
Status
Intervention / Treatment
Detailed Description
Tinostamustine is a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule. It is anticipated that tinostamustine may have activity in various hematological malignancies and solid tumors.
The study consists of 2 stages:
- Stage 1: Dose Escalation to determine Maximum Tolerated Dose (MTD) at the optimal infusion time and the pharmacokinetic (PK) profiles; is expected to enroll between 21 and 48 patients. Stage 1 has now been completed.
- Stage 2: Expansion in five Cohorts, in which approximately 12-16 patients will be enrolled per cohort, for a maximum of 70 patients.
In Stage 1, tinostamustine doses were escalated following the standard 3+3 design. The decision to escalate to the next dose level occurred after all cohort patients completed 3 weeks (21 days) of observation and have been evaluated for safety and toxicity.The starting dose was a 1 hour infusion of 20 mg/m2, and the maximum dose level was 150 mg/m2. Reduced infusion times of 45 minutes and 30 minutes were assessed once the maximum tolerated dose at a 1-hour infusion was determined.
In Stage 2, five cohorts of patients (with relapsed/refractory multiple myeloma (MM); relapsed/refractory Hodgkin's lymphoma; relapsed/refractory peripheral T-cell lymphoma (PTCL); relapsed/refractory cutaneous T-cell lymphoma (CTCL); and relapsed/refractory T-cell Prolymphocytic leukemia (T-PLL) will be enrolled and treated at the recommended Phase 2 dose (RP2D) based on results of Stage 1. For MM patients, treatment will occur on Day 1 and Day 15 of a 28 day cycle. For lymphoma patients, treatment will occur on Day 1 of a 21 day cycle. Patients in each stage of the study are expected to receive a median of four Cycles of therapy, and the maximum number of treatment Cycles allowed is 12.
A sub study portion was added to the protocol as an amendment. In the sub study 6 patients will be treated with 100mg/m2 tinostamustine infusion delivered over 100 minutes.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Caen, France, CS 3001
- CHU de Caen
-
Clermont Ferrand, France, 63000
- CHU ESTAING Service de thérapie Cellulaire et hématologique Clinique
-
Lille, France, 59037
- CHU Lille Service des Maladies du Sang
-
Pessac, France, 33604
- Hôpital Haut Lévêque
-
Pierre Bénite, France, 69495
- Centre Hospitalier Lyon Sud
-
-
-
-
-
Ulm, Germany, 89081
- University Hospital of Ulm, Department of Internal Medicine III
-
-
-
-
-
Bologna, Italy, 40138
- Institute of Hematology "L. A. Seràgnoli", University of Bologna
-
Naples, Italy, I-80131
- National Cancer Institute, Fondazione 'G. Pascale'
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- VU Medisch Centrum
-
Rotterdam, Netherlands, 3015 GD
- Erasmus MC
-
-
-
-
-
Salamanca, Spain, 37007
- Hospital Universitario de Salamanca
-
Santander, Spain, 39008
- Hospital Universitario Marques de Valdecilla
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08908
- Institut Català d'Oncologia de Barcelona
-
-
-
-
-
St.Gallen, Switzerland, 9007
- Kantonsspital St.Gallen
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Cancer Center
-
-
New York
-
New York, New York, United States, 10019
- Columbia University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Seidman Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient willing and able to sign an informed consent.
- Patients age ≥18 years at signing the informed consent.
- Life expectancy > 3 months.
- Diagnosis of relapsed or refractory lymphoid malignancy for which there are no available therapies.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Absolute Neutrophil Count >1,000 µL
- Platelets ≥100,000 µL
- Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 upper limit of normal (ULN).
- Total bilirubin <2.0 mg/dL unless elevated due to known Gilbert's syndrome.
- Creatinine ≤1.5 x ULN.
- Serum potassium and magnesium at least at the lowest limit of normal (LLN) at baseline(before every IMP administration; if it is below LNN, (supplementation is permissible).
- Males and females of child-bearing potential, and their partners, must be willing to use at least two effective forms of birth control during the study drug administration and for at least 90 days after the administration of the study drug to be eligible to participate. Vasectomized partners and patients must be willing to use a secondary method of effective birth control. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.
Specific Eligibility Criteria for Each Patient Cohort in Stage 2 Phase of the Study
Cohort 1: relapsed/refractory multiple myeloma (Recruitment to this cohort stopped Dec 2021) 1. At least one line of prior systemic therapy and no other standard therapy available with proven clinical benefit.
Cohort 2: relapsed/refractory Hodgkin's lymphoma
1. At least two lines of prior therapy and no other standard therapy available with proven clinical benefit.
Cohort 3: PTCL (recruitment to this cohort stopped March 2021)
- Only PTCL patients with histologically or cytologically confirmed Peripheral T-Cell Lymphoma - Not Otherwise Specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), or Anaplastic Large Cell Lymphoma (ALCL).
- At least one line of prior combination therapy and no other standard therapy available with proven clinical benefit
Cohort 4: relapsed/refractory cutaneous T-cell lymphoma (CTCL), subtypes mycosis fungoides (MF) and Sézary syndrome (SS)
- Only CTCL patients with histologically or cytologically confirmed MF or SS with stage IIb to IVb disease based on modified ISCL/EORTC staging.
- At least one line and a maximum of four prior standard systemic therapies and no other standard therapy available with proven clinical benefit.
Cohort 5: PTCL (Recruitment to this cohort stopped March 2021)
Eligibility criteria for sub study:
Diagnosis of relapsed or refractory lymphoma, including Diffuse large B cell lymphoma who failed at least 2 lines of prior systemic therapy, Hodgkin lymphoma who failed at least 3 lines of prior systemic therapy, follicular lymphoma grade 1-3a, marginal zone lymphoma and mantle cell lymphoma who failed at least 2 lines of prior systemic lines of prior therapy, T cell lymphoma (including PTCL, CTCL) who failed at least 2 lines of prior systemic therapy for which there are no available therapies. Patients with bulky disease and Multiple Myeloma patients are excluded from this sub study.
Exclusion Criteria:
- Patients with any central nervous system involvement.
- Patient who had a hematologic malignancy that has transformed.
- Any patient who has relapsed within 100 days of stem cell infusion following an allogenic or an autologous bone marrow transplant.
- Patients with corrected QT (QTc) interval (Fridericia's formula) > 450 msec.
- Patients who are on treatment with drugs known to prolong the QT/QTc interval.
- Any serious medical condition that interferes with adherence to study procedures.
- Patients with a history of another malignancy diagnosed within three years of study enrollment excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Pregnant or breast feeding females.
- New York Heart Association (NYHA) stage III/IV congestive heart failure. The following arrhythmias not adequately controlled, active: atrial fibrillation/flutter with poor rate control, documented sustained ventricular tachycardia (defined as >30 seconds or requiring cardioversion before 30 seconds have elapsed) or TdP.
- Active infections, or other significant co-morbidities [(e.g., active central nervous system metastases and/or carcinomatous meningitis, active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C.
- Previous cancer therapies within three (3) weeks of dosing as long as the patient has recovered to eligibility levels prior to treatment in this study.
- Use of other investigational agents within 30 days or 5 half-lives prior to the first dose of study drug unless patient has recovered from any related toxicities ≥ Grade 1.
- Steroid treatment within seven (7) days prior to study treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to 10 mg PO QD or less seven (7) days prior to study drug administration are allowed.
- Patients on Valproic Acid for any indication (epilepsy, mood disorder) must be excluded from the trial .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tinostamustine (EDO-S101)
EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 10-20 months from beginning of stage 2
|
Determine overall response rate
|
10-20 months from beginning of stage 2
|
Clinical benefit rate by cohort
Time Frame: 10-20 months from beginning of stage 2
|
Determine clinical benefit rate by cohort
|
10-20 months from beginning of stage 2
|
Safety of selected doses in expanded population
Time Frame: 36 months from beginning stage 2
|
Number of participants with treatment-related adverse events as assessed by CTCAE V4.03
|
36 months from beginning stage 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to objective response
Time Frame: 10-20 months after beginning stage 2
|
Evaluate time to objective response by cohort
|
10-20 months after beginning stage 2
|
Duration of response
Time Frame: 10-20 months after beginning stage 2
|
Evaluate duration of response
|
10-20 months after beginning stage 2
|
Progression free survival (PFS)
Time Frame: 32-36 months after beginning stage 2
|
Determine time to progression free survival time for patients who received the RP2D
|
32-36 months after beginning stage 2
|
Overall Survival (OS)
Time Frame: 32-36 months after beginning stage 2
|
Determine the overall survival time for patients who received the RP2D
|
32-36 months after beginning stage 2
|
Maximum Plasma Concentration (Cmax)
Time Frame: 10-20 months after beginning stage 2
|
Determine Cmax using the PK population
|
10-20 months after beginning stage 2
|
Time to Reach Maximum Concentration (Tmax)
Time Frame: 10-20 months after beginning stage 2
|
Determine Tmax using the PK population
|
10-20 months after beginning stage 2
|
Time taken for the plasma concentration to fall by half its original value (t1/2)
Time Frame: 10-20 months after beginning stage 2
|
Determine t1/2 using the PK population
|
10-20 months after beginning stage 2
|
Area Under Curve (AUC)
Time Frame: 10-20 months after beginning stage 2
|
Determine area under the plasma drug concentration-time curve using the PK population
|
10-20 months after beginning stage 2
|
QT (QTc) analysis
Time Frame: 10-20 months after beginning stage 2
|
To perform a concentration corrected QT analysis
|
10-20 months after beginning stage 2
|
Number of patients with treatment-emergent adverse events (TEAEs). TEAEs will be assessed by NCI-CTCAE 4.03
Time Frame: 10-20 months after beginning stage 2
|
Patient safety data will be summarized by disease cohort as well as overall disease cohorts pooled (i.e., MM, Hodgkin's lymphoma, non-Hodgkin's lymphoma, PTCL, T- PLL)
|
10-20 months after beginning stage 2
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sub study cardiac safety
Time Frame: 2 cycles
|
To characterize the effect of tinostamustine at a dose of 100 mg/m2 on cardiac repolarization (QTcF) and other ECG parameters
|
2 cycles
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pier L Zinzani, MD,PhD, University of Bologna Medical Center, Bologna
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Neoplasms
- Lymphoma
- Hematologic Neoplasms
- Multiple Myeloma
- Hodgkin Disease
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
Other Study ID Numbers
- EDO-S101-1001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Tinostamustine
-
Mundipharma Research LimitedCompletedSoft Tissue Sarcoma | Ovarian Cancer | Endometrial Cancer | Small-cell Lung Cancer | Triple-negative Breast CancerUnited States, Canada
-
Mundipharma Research LimitedActive, not recruitingGlioblastoma MultiformeSwitzerland, Spain
-
Mundipharma-EDO GmbHTerminatedMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma ProgressionSwitzerland, United States, Norway
-
Markus JoergerRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Gliosarcoma | MGMT-Unmethylated GlioblastomaUnited States